Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

23 May 2019 : Clinical Research  

Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland

Melania Brzozowska12ABCDEF, Waldemar Wierzba3ADEF, Sylwia Szafraniec-Buryło4ADEF*, Marcin Czech4ADEF, Joanna Połowinczak-Przybyłek5ADEF, Piotr Potemski6ADEF, Andrzej Śliwczyński27ABCDEF

DOI: 10.12659/MSM.914517

Med Sci Monit 2019; 25:3846-3853

Abstract

BACKGROUND: This study aimed to undertake an analysis of ten years of real-world evidence (RWE) on overall survival (OS) following treatment of advanced gastrointestinal stromal tumor (GIST) with imatinib, sunitinib, and sorafenib using data from the Polish National Health Fund.

MATERIAL AND METHODS: Data from the Polish National Health Fund, the sole Polish public payer, identified 1,641 patients with advanced GIST who were treated with imatinib (n=1047), sunitinib (n=457), and sorafenib (n=137). The differences in overall survival (OS) were analyzed.

RESULTS: For patients with advanced GIST, the median follow-up time for patients treated with imatinib was 71 months (95% CI, 64.8–79.2), the median OS was 56.9 months (95% CI, 50.4–61.2), with survival at 12 months (89.5%), 24 months (77.9%), 36 months (66.9%), and 60 months (48.4%). The median follow-up time for patients treated with sunitinib was 41.4 months (95% CI, 34.6–49.3), the median OS was 22.8 months (95% CI, 19.2–26.8), with survival at 12 months (68.2%), 24 months (47.1%), and 36 months (31%). The median follow-up time for patients treated with sorafenib was 17.4 months (95% CI, 14.6–22.9), the median OS was 16.9 months (95% CI, 13.7–24.3), with survival at 12 months (61.9%), at 24 months (36.2%), and at 36 months (16.8%).

CONCLUSIONS: Real-world data collected in a ten-year period confirmed the effectiveness of the use of imatinib, sunitinib, or sorafenib for the treatment of advanced GIST and was comparable with the findings from clinical trials.

Keywords: Abdominal Neoplasms, Population Control, Single-Payer System, Benzamides, Disease-Free Survival, gastrointestinal stromal tumors, imatinib mesylate, Indoles, Poland, Protein Kinase Inhibitors, Public Health Practice, Pyrroles, sorafenib, Sunitinib

Add Comment 0 Comments

Editorial

01 February 2025 : Editorial  

Editorial: Current Approaches to Screening for Lung Cancer in Smokers and Non-Smokers

Dinah V. Parums

DOI: 10.12659/MSM.948255

Med Sci Monit 2025; 31:e948255

0:00

In Press

Clinical Research  

Immune Dysregulation in Acute Herpes Zoster: Predictive Factors for Postherpetic Neuralgia

Med Sci Monit In Press; DOI: 10.12659/MSM.944688  

0:00

Clinical Research  

Inflammatory Biomarkers from Blood Counts as Prognostic Tools in Metastatic Esophageal Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.947202  

Laboratory Research  

Comparison of Color Stability Between Single-Shade and Conventional Composite Resins Following Immersion in...

Med Sci Monit In Press; DOI: 10.12659/MSM.946784  

Clinical Research  

Evaluation of Knowledge, Attitudes, and Practices Toward Thyroid Nodules in 456 Patients with Thyroid Nodules

Med Sci Monit In Press; DOI: 10.12659/MSM.945732  

Most Viewed Current Articles

17 Jan 2024 : Review article   6,966,841

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research   701,694

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Mar 2024 : Editorial   25,087

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...

DOI :10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

28 Jan 2024 : Review article   19,746

A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future

DOI :10.12659/MSM.943912

Med Sci Monit 2024; 30:e943912

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750